Composite
38%
Novelty
Feasibility
Impact
Mechanistic
70%
Druggability
55%
Safety
40%
Confidence
35%

Mechanistic description

This hypothesis proposes that astrocytic TREM2-like receptors (TREML2) regulate synaptic plasticity through a fundamentally different mechanism than microglial TREM2, focusing on synaptic strengthening rather than pruning. TREML2 expressed on astrocytic processes that contact synapses would detect damage-associated molecular patterns (DAMPs) and complement fragments deposited at weakened synapses. Upon activation, astrocytic TREML2 would trigger intracellular signaling cascades involving SYK kinase and PI3K/AKT pathways, leading to increased release of synaptogenic factors including thrombospondins, cholesterol, and BDNF. This astrocytic response would promote synaptic stabilization and strengthening of functionally important connections that might otherwise be targeted for elimination. The hypothesis suggests that astrocytic TREML2 acts as a ‘synaptic rescue’ mechanism, complementing microglial pruning by selectively reinforcing synapses that show signs of activity-dependent plasticity markers such as CaMKII phosphorylation or AMPA receptor trafficking. This dual cellular mechanism would create a balanced synaptic homeostasis system where microglia eliminate weak/inactive synapses while astrocytes strengthen viable but vulnerable connections. Dysregulation of astrocytic TREML2 could lead to either excessive synaptic loss (when rescue mechanisms fail) or pathological synaptic accumulation (when strengthening mechanisms are overactive), contributing to neurodevelopmental and neurodegenerative connectome abnormalities.

Evidence for (5)

  • TREM2 loss-of-function variants increase AD risk 2-4 fold

  • TREM2 is required for microglial response to amyloid plaques

  • TREM2 agonist promotes microglial clustering around plaques and reduces neurite dystrophy

  • Hub regions show heightened connectivity burden correlating with pathology

  • Synaptic loss in AD correlates with dysregulated microglial surveillance

Evidence against (4)

  • AL002c (TREM2 agonist) failed to meet primary endpoint in INVOKE-2 Phase 2 trial (2024)

  • TREM2 deficiency reduces amyloid pathology in some contexts (reduced microglial clustering)

  • Microglial states in AD are heterogeneous - single pathway modulation insufficient

  • Mouse-to-human microglial translation limitations affect validity